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Abstract
Background: CVD in obesity and T2DM are associated with endothelial activation, elevated plasma vascular
inflammation markers and a prothrombotic state. We examined the contribution of FFA to these abnormalities
following a 48-hour physiological increase in plasma FFA to levels of obesity and diabetes in a group of healthy
subjects.
Methods: 40 non-diabetic subjects (age = 38 ± 3 yr, BMI = 28 ± 1 kg/m
2, FPG = 95 ± 1 mg/dl, HbA1c = 5.3 ± 0.1%)
were admitted twice and received a 48-hour infusion of normal saline or low-dose lipid. Plasma was drawn for
intracellular (ICAM-1) and vascular (VCAM-1) adhesion molecules-1, E-selectin (sE-S), myeloperoxidase (MPO) and total
plasminogen inhibitor-1 (tPAI-1). Insulin sensitivity was measured by a hyperglycemic clamp (M/I).
Results: Lipid infusion increased plasma FFA to levels observed in obesity and T2DM and reduced insulin sensitivity by
27% (p = 0.01). Elevated plasma FFA increased plasma markers of endothelial activation ICAM-1 (138 ± 10 vs. 186 ± 25
ng/ml), VCAM-1 (1066 ± 67 vs. 1204 ± 65 ng/ml) and sE-S (20 ± 1 vs. 24 ± 1 ng/ml) between 13-35% and by ≥ 2-fold
plasma levels of myeloperoxidase (7.5 ± 0.9 to 15 ± 25 ng/ml), an inflammatory marker of future CVD, and tPAI-1
(9.7 ± 0.6 to 22.5 ± 1.5 ng/ml), an indicator of a prothrombotic state (all p ≤ 0.01). The FFA-induced increase was
independent from the degree of adiposity, being of similar magnitude in lean, overweight and obese subjects.
Conclusions: An increase in plasma FFA within the physiological range observed in obesity and T2DM induces
markers of endothelial activation, vascular inflammation and thrombosis in healthy subjects. This suggests that
even transient (48-hour) and modest increases in plasma FFA may initiate early vascular abnormalities that promote
atherosclerosis and CVD.
Background
Endothelial cells (ECs) play a key role in the transport of
metabolic substrates and cells between the blood and
the interstitial space, including a complex signalling sys-
tem that regulates innate and immune responses of the
vascular bed [1,2]. Transendothelial migration of leuko-
cytes is regulated by soluble cell adhesion molecules
such as intercellular adhesion molecule-1 (ICAM-1),
vascular adhesion molecule-1 (VCAM-1) and E-selectin.
Their expression is increased as ECs are activated by
proinflammatory stimuli such as bacterial endotoxins,
Il-1b or TNF-a, CRP, oxidized LDL or hemodynamic
forces related to blood flow [3,4]. EC activation involves
the NF-Kb and other intracellular inflammatory path-
ways and play a key role in the early development of the
inflammatory response in atherosclerosis [3-7]. Athero-
sclerosis in obesity, metabolic syndrome and T2DM is
initiated by damage/activation of the endothelium
[2,4,8]. Plasma measurement of cell adhesion molecules
are accepted markers of endothelial dysfunction and
vascular disease [9-16]. Endothelial activation has pro-
coagulant consequences that can be measured as a
change in the balance of tissue plasminogen activator
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any medium, provided the original work is properly cited.and its endogenous inhibitor, tissue plasminogen activa-
tion inhibitor-1 (tPAI-1 or PAI-1) [17]. Plasminogen
activator inhibitor 1 is the primary physiological inhibi-
tor of tissue-type plasminogen activator and urokinase-
like plasminogen activator and inhibits both fibrinolysis
and proteolysis [17,18]. Insulin resistant states such as
obesity and T2DM are known prothrombotic states
characterized by elevated PAI-1 levels [19]. In the Insu-
lin Resistance Atherosclerosis Study, plasma C-reactive
protein and PAI-1 levels were enhanced in insulin-resis-
tant subjects who later developed diabetes, and PAI-1
levels predicted diabetes independently of other known
risk factors [20]. However, the role of plasma FFA in
thrombogenesis in humans is poorly established and no
strong direct evidence is available.
Myeloperoxidase (MPO) is an enzyme derived from
granules in activated neutrophils, monocytes and some
tissue macropahges that catalyzes the formation of a
number of reactive oxidant species (ROS) by the genera-
tion of chlorinating, nitrating, and other oxidizing species
[21]. These products may initiate lipid peroxidation and
promote post-translational modification of target pro-
teins as part of the innate immune response. MPO and
its reactive oxygen species (ROS) are enriched in human
atheroma plaques [22-26] and increase within the area of
infarct after an acute myocardial infarction [24,27].
Increased plasma levels of MPO independently predict
endothelial dysfunction and coronary artery disease
(CAD) [21], even after adjusting for traditional risk fac-
tors or hsCRP. In subjects presenting with acute coronary
events, serum MPO levels is a strong predictor of adverse
cardiac outcomes [28-30]. Circulating MPO concentra-
tions also predict future CAD in otherwise healthy indivi-
duals [31]. Finally, decreased plasma levels of MPO
secondary to specific MPO polymorphisms appear to be
cardioprotective in humans [28,32-35]. Taken together,
the available evidence highlights the importance of MPO
to cardiovascular disease although the factors modulating
its activity in humans remain poorly understood.
There is an increasing awareness about the potential
role for FFA in atherosclerosis [36,37], although this
area has been relatively neglected in the field. It has
been noted that FFA may increase the production of
multiple cytokines by mononuclear cells with generation
of ROS and activation of pro-inflammatory NF-B path-
ways in human endothelial cells [8]. Pharmacologic
increases of plasma FFA (i.e., 5-fold elevation) by lipid
infusion cause endothelial dysfunction and may alter
plasma sCAM concentrations in healthy subjects
[38,39], but the clinical relevance is not clear because
these studies increased plasma FFA well beyond the
physiological range.
With the widespread epidemic of obesity and diabetes,
we carried out a proof-of-concept study to understand
the role of elevated plasma FFA in relation to endothe-
lial activation, vascular inflammation, MPO expression
and the promotion of a prothrombotic state. The role of
FFA on early steps of atherogenesis could have far
reaching implications regarding the prevention and
treatment of cardiovascular in obesity and T2DM.
Research Design & Methods
Subjects
Forty subjects participated in the study. Their clinical
and laboratory characteristics are shown in Table 1. All
subjects had a normal 75-gram oral glucose tolerance
test (OGTT) performed at our clinical research unit.
Physical activity was avoided in the days prior to testing
or between study admissions. Body weight and degree of
physical activity were stable in all subjects for at least 3
months prior to enrolment. No subjects had any evi-
dence of cardiac, hepatic, renal or any other organ sys-
tem disease, as determined by a complete medical
history, physical examination, electrocardiogram, routine
blood work, and urinalysis. No participants were receiv-
ing any medications known to affect carbohydrate meta-
bolism. Tobacco users were excluded from participation
because smoking alters insulin sensitivity and endothe-
lial function. Each subject gave written informed con-
sent before participation. The study protocol was
approved by the Institutional Review Board of the Uni-
versity of Texas Health Science Center at San Antonio,
Texas.
Experimental design
After the initial screening visit, all subjects were
admitted to the research un i ta t0 7 0 0ho nd a y1 ,f o l -
lowing a 12-hour fast. Subjects were admitted twice 2-4
weeks apart, for the infusion in random order of normal
saline or lipid (Liposyn III, a 20% triglyceride emulsion
Table 1 Patient Characteristics
N (male/female) 40 (19/21)
Age (years) 38 ± 3
BMI (kg/m
2)2 8 ± 1
Fasting plasma glucose (mg/dl) 95 ± 1
2-hr plasma glucose (mg/dl) 120 ± 3
HbA1c (%) 5.3 ± 0.1
Fasting plasma insulin (μU/ml) 9 ± 1
2-hr insulin (μU/ml) 47 ± 7
Fasting plasma FFA (μU/ml) 544 ± 31
2-hr plasma FFA (μU/ml) 122 ± 7
Triglycerides (mg/dl) 104 ± 8
HDL-cholesterol (mg/dl) 44 ± 2
Systolic blood pressure (mmHg) 124 ± 3
Diastolic blood pressure (mmHg) 72 ± 2
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Page 2 of 9largely composed of soybean oil). Lipid or saline were
infused at a constant rate of 0.5 ml/min (30 ml/hour)
during the entire 2-day admission through an antecubi-
tal forearm vein. The lipid infusion was set to achieve a
target day-long plasma free fatty acid (FFA) concentra-
tion of ~600 μmol/l, similar to that of subjects who are
obese or have T2DM. Participants received a weight-
maintaining diet prepared by the research dietician, con-
sisting of 50% carbohydrate, 30% fat, and 20% protein.
Meals were given at 0800 h, 1200 h, 1800 h, and 2100 h
with a caloric distribution of 30%, 30%, 30% and 10% of
total daily calories in each meal, respectively. Subjects
consumed identical meals during each hospital admis-
sion. Complete food intake was confirmed after each
meal by a research nurse. During days 1 and 2, blood
was drawn every 2 hours from 0800 h through midnight
and overnight every 4 hours for the determination of
plasma glucose, C-peptide, insulin and FFA concentra-
tions. On day 3, starting at 0700 h patients underwent a
2-hour hyperglycemic clamp. Blood was drawn for the
measurement of serum ICAM-1, VCAM-1, MPO, E-
selectin, tPAI-1 fasting in 2 separate samples 10 minutes
apart before the start of the hyperglycemic clamp.
Patients were discharged after completion of the hyper-
glycaemic clamp test. All procedures were performed in
an identical fashion in both admissions.
Hyperglycemic clamp
On day 3 and after an overnight fast, subjects under-
went a hyperglycemic clamp as described previously by
our group [40,41] to assess insulin sensitivity as the
metabolic clearance of glucose (M) divided by the
plasma insulin concentration (I) (or M/I). In brief, a 20-
gauge Teflon catheter was inserted into an antecubital
vein at 0800 h for the infusion of 20% dextrose. A sec-
ond vein on the dorsum of the hand is cannulated retro-
gradely for the collection of blood samples, and the
hand placed in a thermoregulated box at 65°C to
achieve arterialization of the venous blood. Both intrave-
nous lines are kept patent with a slow infusion of nor-
mal saline. After the collection of baseline samples,
plasma glucose concentration is acutely raised by 125
mg/dL above the basal level and the desired hyperglyce-
mic level is maintained (± 5%) for the following 120
min by periodic adjustment of a 20% glucose infusion
based upon the negative feedback principle.
Analytical determinations
The plasma glucose concentration was determined in
duplicate by the glucose oxidase method with a Beckman
Glucose Analyzer II (Beckman Instruments Inc, Fuller-
ton, CA). Plasma insulin and C-peptide concentrations
(Coat-A-Count Insulin, Diagnostic Products Corp., Los
Angeles, CA) were determined by radioimmunoassay.
Plasma FFA concentration was measured by standard
colorimetric methods. Plasma ICAM-1, VCAM-1, MPO,
E-selectin and tPAI-1 concentrations were assayed by
enzyme linked immunosorbent assay (Lincoplex assay,
Millipore Corp., MA).
Statistical analysis
All values presented as the mean ± standard error of the
mean. Within-group differences were determined by the
paired two-tailed Student’s t test. Normal distribution
was checked before all analyses, and nonparametric esti-
mates were used when appropriate. Comparisons were
considered statistically significant if the P value was <
0.05. Where appropriate regressions were calculated by
least squares linear correlation coefficients analysis. Ana-
lysis were performed using JMP software for Macintosh
(SAS institute INC, Cary, NC).
Results
Plasma glucose, FFA and hormone concentrations during
the 48-hour saline and lipid infusion
The plasma glucose, FFA, C-peptide and insulin concen-
trations during the 48-hour saline or lipid infusions are
shown in Table 2. Mean 48-hour plasma FFA concen-
tration increased significantly during the lipid infusion
from 422 ± 80 to 588 ± 111 μmol/L (p < 0.001). There
was a small but significant increase in mean 48-hour
plasma glucose during lipid infusion compared to saline
infusion (94 ± 18 to 97 ± 18 mg/dl, p < 0.02). This was
likely a consequence of FFA-induced insulin resistance
as evidenced by the increase in the mean plasma insulin
and C-peptide concentration during the 48-hour lipid
infusion (p = 0.01 and p = 0.04, respectively; Table 2).
Effect of a 48-hour increase low-dose lipid infusion on
insulin sensitivity (Figure 1)
Lipid infusion significantly decreased insulin sensitivity
a ss h o w ni nF i g u r e1w i t ha2 7±4 %r e d u c t i o na sm e a -
sured by the M/I index (p = 0.01). This observation
made evident that a mild physiological increase in
plasma FFA by a short-term (48-hours) low-dose lipid
infusion is capable of profound metabolic effects in
healthy humans, consistent with prior observations by
our group [41,42].
Table 2 Effect of Lipid Infusion on Metabolic Parameters
48-hour mean values Saline Lipid
Glucose (mg/dl) 94 ± 18 97 ± 18*
FFA (μmol/L) 422 ± 80 588 ± 111**
Insulin (μU/ml) 8 ± 1 12 ± 2
†
C-peptide (ng/ml) 3.3 ± 0.6 3.9 ± 0.7
††
*p = 0.02; **p < 0.001;
†p = 0.01;
††p = 0.04
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plasma concentrations of markers of endothelial
activation, MPO and tPAI-1
Compared to a 48-hour saline infusion, lipid infusion
led to increased plasma ICAM-1 by 35 ± 5% (from 138
± 10 vs. 186 ± 25 ng/ml), VCAM-1 by 13 ± 3% (1066 ±
67 vs. 1204 ± 65 ng/ml, both p < 0.001) and E-selectin
b y1 7±1 %( 2 0±1v s .2 4±1n g / m l ,p=0 . 0 0 6 )l e v e l s
(Figure 2). The mean plasma FFA levels achieved with
lipid infusion correlated closely with all plasma endothe-
lial activation markers: ICAM (r = 0.38, p = 0.03),
VCAM-1 (r = 0.48, p < 0.01) and E-selectin (r = 0.48,
p < 0.01).
Plasma MPO and tPAI-1 levels were also altered by
FFA elevation and to a greater extent. Compared to a
saline, FFA increased doubled plasma MPO from 7.5 ±
0.9 to 15 ± 25 ng/ml (p = 0.01) and tPAI-1 by 132%
from 9.7 ± 0.6 to 22.5 ± 1.5 ng/ml (p < 0.001) (Figure 3).
Figure 4 summarizes the percent increase with lipid
infusion of markers of endothelial activation, MPO and
tPAI-1. The increase in plasma FFA achieved with
lipid correlated very strongly (r = 0.69, p < 0.001)
w i t ht h ei n c r e a s ei np l a s m at P A I - 1 ,s u g g e s t i n gac l o s e
relationship between FFA and induction of a prothrom-
botic state under these experimental conditions.
Finally, we explored if total body fat could modify or
play a role in the marked increase in sCAM, MPO or
tPAI-1 response to 48-hour FFA stimulation. Figure 5
describes the response in subjects divided by BMI as
either lean (BMI <25 kg/m
2), overweight (BMI >25 and
<30 kg/m
2) or obese (BMI >30 kg/m
2). No significant
differences were appreciated for any variable based on
BMI, suggestive of a direct effect of FFA-induced
endothelial activation independent of total adiposity.
Discussion
Few clinical studies have examined the role of FFA as a
trigger for endothelial activation, inflammation and
thrombosis. This has been overlooked in favour of a
focus on traditional cardiovascular risk factors or
detailed studies on lipoprotein metabolism. With obesity
and T2DM reaching epidemic proportions, it is impor-
tant to assess the role of excessive FFA supply regarding
endothelial injury and inflammation because both condi-
tions are characterized by increased rates of lipolysis and
plasma FFA due to adipose tissue insulin resistance. In
order to have clinical relevance, the study carefully
mimicked the plasma FFA levels characteristic of obese
and diabetic patients and assessed their impact by using
validated plasma markers of endothelial activation, sys-
temic inflammation and thrombosis.
Serum cellular adhesion molecule levels increase in
association with cardiovascular risk factors and are asso-
ciated with structural functional measures of athero-
sclerotic disease, as well as with adverse cardiovascular
prognosis [9,11,15,43,44]. Serum VCAM-1, ICAM-1 and
Figure 1 Effect of a 48-hour increase low-dose lipid infusion on
insulin sensitivity
Figure 2 Effect of a 48-hour increase low-dose lipid infusion on plasma concentrations of markers of endothelial activation, MPO and
tPAI-1
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chronic renal failure [48], in lean and obese subjects
genetically predisposed to T2DM [39,49] and in T2DM
[16,50]. Recently, ICAM-1 and E-selectin were reported
to predict future development of T2DM, even after
accounting for classical risk factors such as age, BMI,
family history of T2DM, hsCRP and others [51]. Taken
together, these studies are an indication of the value of
elevated plasma VCAM-1, ICAM-1 and E-selectin levels
to assess early systemic inflammation and EC activation.
Elevated plasma FFA offer a unifying mechanism as a
cause not only for the development of insulin resistance,
as reported in the literature (reviewed by Cusi in [52])
and observed in this study, but as a factor actively
involved in the higher cardiovascular risk of obese and
insulin-resistant populations. The results of this study
also highlight the susceptibility of ECs to modest
increases in plasma FFA, as endothelial activation was
induced with just a 2-day low-dose lipid infusion. How-
e v e r ,i tm u s tb er e c o g n i z e dt h a tf u t u r es t u d i e ss h o u l d
examine the role of FFA using gold-standard techniques
to assess endothelial function [11] and evaluate their
long-term effect on the vascular bed. Finally, because
the magnitude of the elevation of sCAM was indepen-
dent of adiposity and pre-existing insulin resistance (i.e,
overweight and obese vs. lean subjects; Figure. 5), this
renders further support for the hypothesis of a direct
effect of plasma FFA elevation to induce markers of
endothelial activation and vascular inflammation.
Indeed, there was a strong correlation between the
plasma FFA level achieved by lipid infusion and the ele-
vation on biomarkers of EC activation.
The novel finding that a mild elevation in plasma FFA
may activate vascular MPO and tPAI-1 has important
clinical implications. The mechanisms by which MPO
may promote atherogenesis include conversion of LDL
into more atherogenic oxidized particles (oxLDL), oxida-
tive modification of apolipoprotein A-I that results in a
dysfunctional HDL and reduction of EC nitric oxide
availability resulting in endothelial dysfunction
[21-24,26,53-55]. These multiple mechanisms help
explain the strong predictive value of plasma MPO
levels for acute coronary syndromes (ACS) in humans
even after adjusting for traditional cardiovascular risk
Figure 3 Compared to a saline, FFA increased doubled plasma MPO from 7.5 ± 0.9 to 15 ± 25 ng/ml (p = 0.01) and tPAI-1 by 132%
from 9.7 ± 0.6 to 22.5 ± 1.5 ng/ml (p < 0.001)
Figure 4 This figure summarizes the percent increase with lipid
infusion of markers of endothelial activation, MPO and tPAI-1
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Page 5 of 9factors, Framingham risk score, or hsCRP [28-30]. For
instance, Zhang et al [28] in a case-control study in a
tertiary care referral center, compared 158 patients with
documented CAD against 175 patients without angio-
graphically significant CAD (controls) and found that
both leukocyte- and blood-MPO levels were significantly
greater in patients with CAD with an odds ratio (OR) of
20.4 (95% CI, 8.9-47.2) for the highest vs. lowest quar-
tiles of plasma MPO levels. Brennan et al [29] studied
604 patients who presented at the emergency room with
ACS and reported that those with the highest MPO
quartile has a 3.9-fold higher risk of having a CHD
event and an even higher predictive value in the next 6
months. Similar results have been reported by Baldus et
al [30]. Plasma MPO has been accepted to be a good
biomarker of endothelial dysfunction [56] and predicted
cardiovascular events even in 1,138 apparently healthy
subjects in the EPIC-Norfolk Prospective population
study [31]. MPO-triggered EC apoptosis, intracoronary
erosions and thrombus formation has been proposed
based on work by Sugiyama, Libby et al [24]. This link
may be further strengthened by this report and may
point to elevated FFA as a common pathogenic mechan-
ism for endothelial dysfunction, inflammation and
thrombogenesis.
Several mechanisms may explain how lipid infusion
may induce endothelial activation and eventual damage.
Elevation of plasma FFA by lipid infusion activates pro-
i n f l a m m a t o r yg e n e ss u c ha sT N F - a,w h i c hi sap o t e n t
stimulator of sCAMs and MPO secretion [8,36,37]. In
vitro studies in endothelial and vascular smooth muscle
cells have provided evidence that FFA increase oxidative
stress and inflammation by activating the NF-Bp a t h -
way and increasing the formation of ROS by mononuc-
lear cells, which initiate the inflammatory process
involving the endothelium. Recent studies indicate that
there is a clear fatty acid dose-response impairment of
insulin signalling, inhibition of nitric oxide production
and activation of NF-B activity in bovine aortic
endothelial cells [57] and in mononuclear cells of
Figure 5 Figure5describes the response in subjects divided by BMI as either lean (BMI <25 kg/m
2), overweight (BMI >25 and <30 kg/m
2)
or obese (BMI >30 kg/m
2)
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increases in plasma FFA [38]. Human monocytes
exposed for just 48 hours to excessive lipids have a
dose-dependent increase in intercellular ROS and
increased adhesion to ECs, mediated by an increase in
integrin CD11b cell surface expression [58]. In healthy
subjects, fatty acid-induced oxidative stress and
endothelial activation with an increase in plasma
TNF-a, IL-6, ICAM-1 and VCAM-1 can be induced by
a single high-fat meal [59]. Endothelial dysfunction has
been reported to be reversible with lifestyle changes
[60], anti-inflammatory agents such as salicylates [61] or
by insulin-sensitizers such as thiazolidinediones [62].
Thus, increased lipid infusion and/or plasma FFA
appears to be an early trigger for multiple pathways
leading to atherogenesis, independent of FFA-induction
of muscle or liver insulin resistance. A limitation of the
study is that there is no commercially available mixture
that mimics the human fatty acid profile. We used Lyp-
soyn III that is 100% soybean oil, which is composed of
largely unsaturated long chain fatty acids, with 55%
linoleate, 22% oleate, 11% palmitate and 4% stearate
while plasma is higher in more saturated fatty acids with
11% linoleate, 38% oleate, 28% palmitate and 12% stea-
rate [63]. The overall impact of different fatty acids on
the vascular bed has not been carefully characterized in
humans but in skeletal muscle palmitate may induce
insulin resistance to a greater extent than other fatty
acids [64]. However, this has not been confirmed in
others studies in which linoleate, oleate and palmitate
had similar inhibitory effects on glycogen synthesis and
insulin-stimulated muscle glucose uptake [65,66]. Clearly
more work is needed in this field but unfortunately
plasma FFA have been poorly studied and overall
neglected as relevant in the pathogenesis of athero-
sclerosis in humans. We believe that this proof-of con-
cept study may be a provocative and valuable
contribution to stimulate future work in this area.
Conclusions
We have demonstrated that a sustained low-dose lipid
infusion leading to a modest increase in plasma FFA
concentration is sufficient to induce endothelial activa-
tion, increase plasma myeloperoxdase levels and pro-
mote a prothrombotic state in non-diabetic healthy
subjects. Taken together, these results provide direct
evidence in humans that mild short-term lipid-oversup-
ply is sufficient to initiate early vascular abnormalities
that may lead to atherosclerosis and CVD.
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